• Plenary
  • Workshop
  • Side Meeting
  • 08:00

    Registrations and refreshments

    Time: 08:00

  • 09:30

    Opening session and Partner introductions

    Time: 09:30

    Plenary

    The official opening ceremony from the Partners, hosts and officials of the World Hepatitis Summit 2017. This session will outline the expected contributions from civil society, government and WHO Member States in advancing the viral hepatitis agenda.

    Welcome and introductions:

    • World Hepatitis Alliance.

    • World Health Organization.

    • Brazilian delegation.

    • UNITAID.

    • NOhep Visionaries.

  • 11:00

    Break

    Time: 11:00

  • 11:30

    Setting the global scene

    Time: 11:30

    Plenary

    This opening plenary session looks at the opportunities and challenges that lie ahead in the global implementation of viral hepatitis plans.

    Worldwide, approximately 240 million people have chronic hepatitis B infection and 80 million people have chronic hepatitis C infection - two liver infections that together result in an estimated 1.4 million deaths worldwide. A stepped-up global response can no longer be delayed.

    Presentations:

    • Patient testimonials.
    • Lancet commission.
  • 13:00

    Lunch

    Time: 13:00

  • 14:00

    Strategic direction 1: strategic information for focused action

    Time: 14:00

    Plenary

    Session Lead: Sharon Hutchinson

    The Summit’s agenda takes the Global Health Sector Strategy on Viral Hepatitis (GHSS) - and its 5 strategic directions - as its framework. In this plenary session, strategic direction 1 looks at advocacy, political commitment and national planning.

    Presentations:

    • Global viral hepatitis situation and response.
      Yvan Hutin, WHO
    • Progress in integrating civil society in the global viral hepatitis response.
      Raquel Peck, World Hepatitis Alliance
    • Country examples demonstrating the role of strategic information in national planning.

    Session objectives:

    To highlight:

    • The role and importance of strategic information in planning and monitoring national responses.
    • The priority actions for countries and role of WHO in supporting countries.
    • The latest data on the global viral hepatitis situation and response.
    • Progress made in integrating civil society in the global viral hepatitis response and on global awareness activities.
    • Country examples demonstrating the important role of strategic information for focused action.
  • 15:30

    The critical role of strategic information : HCV elimination in Georgia

    Time: 15:30

    Parallel workshop

    Session Lead: Francisco Averhoff

    Presentations:

    • Assessing the burden of disease: the planning, conduct and use of a National Seroprevalence Survey.
    • Monitoring the care cascade: developing a robust screening and Treatment Intervention System.
    • Research and project evaluation.
    • Project oversight and guidance: the role of the Technical Advisory Group.

    Session objectives:

    • Learn the importance of a well conducted population serosurvey to guide development of an evidence-based national strategy/plan.
    • Understand the importance of a robust strategic information system to guide and monitor an elimination program.
    • Learn the key role of partnerships in developing a world class information system.
  • 15:30

    How to develop a national plan on viral hepatitis?

    Time: 15:30

    Parallel workshop

    Session Lead: Hande Harmanci

    Presentations:

    • Developing a national plan: introduction.
      Hande Harmanci
    • The importance of national planning.
    • Identifying the best processes to create national plans.
    • Critically appraise a sample national hepatitis plan using a checklist.

    Session objectives:

    • Learn to differentiate between national strategies and plans.
    • Identify the best processes to create national plans.
    • Use a checklist to align national plans with the Global Health Sector Strategy on Viral Hepatitis.
    • Critically appraise a national plan for comprehensiveness.
  • 15:30

    How to develop an investment case?

    Time: 15:30

    Parallel workshop

    Session Lead: Yvan Hutin

    Presentations:

    • An investment case: The why and the proposed WHO approach.
      Yvan Hutin and Razia Pendse
    • Indian case study: Need for an investment case.
      Razia Pendse
    • Breakout interactive session.
    • Debrief of the solution to the exercise.
      Rakesh Aggarwal
    • WHO wrap-up: How economic analysis was used in the case of Egypt.

    Session objectives:

    • Describe the role of an investment case/economic analysis in the national planning process.
    • Differentiate a cost effectiveness analysis from health care perspective from a broader cost-benefit analysis/investment case.
    • Identify the elements needed for a national investment case/economic analysis in practice.
  • 15:30

    How data can help mobilize societies?

    Time: 15:30

    Parallel workshop

    Session Lead: Achim Kautz

    Presentations:

    • Introduction.
    • Presentation from a communications expert.
    • Examples, data selection, interaction of NGOs and governments.
    • The US example.
    • Discussion.

    Session objectives:

    • Lessons learnt from global awareness strategies in other fields.
    • Lessons learnt from major hepatitis awareness strategies.
    • Identify key data needed to structure awareness strategies.
    • How a global awareness strategy can be used - based on local data - at a local level?
  • 17:00

    Close of day 1

    Time: 17:00

  • 17:30

    Putting a stop to hepatitis A

    Time: 17:30

    Side meeting

    This evening side meeting will examine what is being done to successfully combat hepatitis A, a virus which can lead to epidemics that are explosive and cause substantial economic loss. The focus of this session will be on water, sanitation, hygiene and immunization strategies, featuring success stories and exploring the existing hurdles to overcome in the path towards elimination.
  • 17:30

    UNITAID’s role in hepatitis C

    Time: 17:30

    Side meeting

    This evening side meeting presents UNITAID’s investment and operating model in the context of the emerging global response to hepatitis C. It will share the results of UNITAID-funded projects related to hepatitis C. It will also explore opportunities for potential future investments. 


    This early morning side meeting will look at
  • 07:30

    End of viral hepatitis? Not without tackling hepatitis E!

    Time: 07:30

    Side meeting

    This early morning side meeting will look at this neglected virus and the limited strategies to control and key challenges/opportunities around it. Hepatitis E is the most common cause of acute viral hepatitis worldwide. It’s a cause of 3·3 million symptomatic cases each year and 57 000 hepatitis E related deaths in Asia and Africa where the disease is both endemic and causes large-scale outbreaks. Hepatitis E is also increasingly being recognized as an important emerging infection in high-income countries. With no no efficacious treatment available for acute fulminant hepatitis E and the limited impact of improvements on safe water and sanitation access in displaced populations, this meeting will examine what can be done to limit the burden worldwide. 
  • 08:00

    Registrations and refreshments

    Time: 08:00

  • 09:30

    Strategic direction 2: interventions for impact and strategic direction 3: delivering for equity

    Time: 09:30

    Plenary

    The second day of the Summit is dedicated to strategic directions 2 and 3, which cover the issues of "interventions for impact" and "delivering for equity".

    Presentations

    • Conclusions from the World Hepatitis Summit 2015 and progress made.
      Charles Gore, World Hepatitis Alliance
    • Modelisation of HBV and HCV elimination.
    • Diagnostics: present and future.
    • Access to treatment.
    • Services for key populations - PWID, aboriginal people, prisoners, MSM.

    Session objectives:

    • Learn areas of innovation and neglected issues.
    • Hear about the core issues for elimination and equitable access.
    • Gain an overview of the main advocacy areas and gaps.
  • 11:00

    Break

    Time: 11:00

  • 11:30

    Testing interventions

    Time: 11:30

    Parallel workshop

    Session Lead: Francesco Negro

    Presentations:

    • WHO testing guidelines.
    • Overview of rapid assays for viral hepatitis agents: what test for what setting?
    • Are screening campaigns feasible and acceptable: the PROLIFICA experience
    • The national strategy plan in Georgia.

    Session objectives:

    • Review the scientific, logistical, ethical and political process leading to the implementation of state-of-the-art testing for viral hepatitis.
    • Discuss the feasibility and validity of diagnostic algorithm simplifications.
    • Define what testing strategies should be applied in different settings.
    • Discuss the preliminary results of testing strategies in selected areas.
  • 11:30

    Treatment interventions

    Time: 11:30

    Parallel workshop

    Session Lead: Saeed Sadiq Hamid

    Presentations:

    • The impact of generics in scaling up treatment.
    • Treatment in the private vs public sector.
    • What price for what drug: is there a science to it?
    • Decentralization and ECHO.

    Session objectives

    • Highlight the impact various factors have had in significantly up scaling treatment, particularly in the LMIC.
    • Identify what treatment intervention strategy would work best in their own environments.
  • 11:30

    Prevention interventions

    Time: 11:30

    Parallel workshop

    Session Lead: Niklas Luhmann

    Presentations:

    • WHO injection safety project.
    • Mother to child/vertical transmission and birth dose vaccination.
    • HCV prevention among people who use drugs: evidence and ways forward.
      Niklas Luhmann
    • Blood safety.

    Session objectives:

    • Discuss different core areas of viral hepatitis prevention.
    • Hear country examples of good practice for health facility injection safety, vertical transmission and blood product safety.
  • 11:30

    Delivering equitable services

    Time: 11:30

    Parallel workshop

    Presentations:

    • Introduction.
    • Distribution of work booklet presenting an equity lens
      - Individuals and small groups scoring comparative scenarios against an equity standard.
    • Report back.
    • Summary.

    Session objectives:

    • Understand the concept of an "equity lens".
    • Apply an equity framework to policy/service settings relevant to viral hepatitis.
  • 11:30

    Delivering high quality hepatitis services

    Time: 11:30

    Parallel workshop

    Presentations:

    • Australia service delivery model.
    • HCV testing, treatment and care of people who inject drugs: lessons from Georgia, Kenya and Vietnam.
      Julie Bouscaillou, MdM
    • Ukraine case study.
      Ludmila Maistat
    • HBV diagnostics and indigenous people in Alaska.

    Session objectives:

    • Review examples of service delivery models for different population groups.
    • Discuss gaps in HBV vaccination, HBV and HCV testing, diagnosis, treatment and care cascade for key populations in different settings and possible solutions to filling in the gaps.
    • Assess the role of case management; peer-to-peer support in community-based or community oriented service delivery.
  • 13:00

    Lunch

    Time: 13:00

  • 14:00

    Parallel workshops

    Time: 14:00

    Parallel workshop

    Parallel workshops from 11.30am repeated. Choose from:

    • Testing interventions
    • Treatment interventions
    • Prevention interventions
    • Delivering equitable services
    • Delivering high quality hepatitis services
  • 15:30

    Access and Intellectual Property

    Time: 15:30

    Panel

    This closing panel session examines how to develop the uninterrupted supply of quality-assured vaccines, medicines, diagnostics and other commodities on which effective hepatitis programmes are dependent.

    Presentations:

    • Introduction: Overcoming IPs.
    • Patent opposition.
    • Direct price negotiations.
    • Compulsory licensing.
    • Voluntary licensing.
    • Open discussion with audience.

    Objectives:

    • To provide an overview of key IP barriers to access hepatitis C treatment.
    • To review different approaches to overcoming price and IP barriers and the progress made.
    • To discuss the possibility for organisations and civil society groups applying different methods and approaches to scaling up access to hepatitis C treatment to be complementary in their strategies.

     

  • 17:00

    Close of day 2

    Time: 17:00

  • 17:30

    Hepatitis in children

    Time: 17:30

    Side meeting

    This evening side meeting looks at hepatitis B and C in children and adolescence. The session will explore some of the recent advances in pediatrics as well as the unique challenges that still need to be overcome within this area.

    Thisj

     
    TThis evening side meeting presents

    adolescence
  • 17:30

    Addressing the neglected burden of hepatitis D

    Time: 17:30

    Side meeting

    This evening side meeting will examine the challenges around the hepatitis D epidemic and what is being done to tackle it. Case studies will include Brazil’s response to the disease in the north of the country as well as highlights from the World Indigenous Peoples Conference on Viral Hepatitis (August 2017, Alaska).

  • 07:30

    Integration and hepatitis service delivery

    Time: 07:30

    Side meeting

    This early morning side meeting will look at developing integrated hepatitis service delivery. It will examine when it is appropriate to integrate; what opportunities exist for integration and the lessons we've learned from HIV and TB.

  • 07:30

    Lancet Commission: accelerating the elimination of viral hepatitis

    Time: 07:30

    Side meeting

    This early morning side meeting will introduce the Lancet Commission for viral hepatitis and its key recommendations in overcoming the barriers to elimination with specific attention paid to the challenges of high burden areas. The meeting will also explore some of the methods used globally as part of different regional and national initiatives.

  • 08:00

    Registrations and refreshments

    Time: 08:00

  • 09:30

    Strategic direction 4: financing for sustainability

    Time: 09:30

    Plenary

    Session Lead: Charles Gore

    The first of two plenary sessions on strategic direction 4, which addresses the sustainable financing of hepatitis responses within a whole health systems approach.

    Presentations:

    • Financing for hepatitis within a whole health systems approach - a panel discussion.
      Jeremy Lauer, WHO
      David Wilson, World Bank
      Various national governments
    • Pooled procurement - PAHO's Strategic and Revolving Funds.
    • Pooled procurement - The new Global Procurement Fund.
      Homie Razavi, Center for Disease Analysis

    Session objective:

    • Learn how countries can best approach sustainable financing for hepatitis.

  • 11:00

    Break

    Time: 11:00

  • 11:30

    Strategic direction 4: financing for sustainability

    Time: 11:30

    Plenary

    Session Lead: Charles Gore

    This session examines the potential sources of hepatitis financing that will be required for countries to launch, accelerate and sustain public health responses to viral hepatitis.

    Presentations:

    • Financing HBV vs HCV.
    • External and domestic financing: the changing balance and the new reality.
    • Engaging with Ministries of Finance.
      Eduardo González-Pier, Center for Global Development
    • Public and private sector collaboration.
    • Public-private partnerships in testing.
    • A strategic approach to financing hepatitis.
      Charles Gore, World Hepatitis Alliance

    Session objectives:

    • Learn the best approach to financing for HBV and HCV - separately or together.
    • Recognise the different sources of financing available to countries.
    • Learn how to ensure the support of Ministries of Finance.
    • Understand how the public and private sector can be combined.
    • Discover how to approach hepatitis financing in a structured way.

  • 13:00

    Lunch

    Time: 13:00

  • 13:00

    Dedicated Funding for Elimination of Viral Hepatitis

    Time: 13:00

    A lunchtime roundtable co-organized by HEP2030 and GPRO

    As national strategies and action plans are being formulated and put into practice for elimination of hepatitis, an increasing sense of urgency has emerged regarding the funding for technical support, capacity building, and financing for hepatitis screening and treatment. In response to this, two new organizations, HEP2030 and GPRO, strive to fill the void by being a catalyst and enabler for the global effort. Participants are encouraged to share their thoughts on how the two funds can best serve the global movement to eliminate viral hepatitis.

    Limited spaces available.
  • 14:00

    Strategic direction 5: Innovation for acceleration

    Time: 14:00

    Plenary

    Session Lead: Joseph Tucker

    Innovation can help drive towards the overall objective of hepatitis elimination in a wide range of settings. This innovation session will highlight innovations related to hepatitis B and C products, programs and policies.

    Presentations:

    • Introduction and importance of innovation.
    • Innovation plenary.
    • Product innovation.
      Francesco Marinucci and submissions finalist(s)
    • Program innovation.
      Joseph Tucker and submissions finalist(s)
    • Policy innovation.
      Bobby John and submissions finalist(s)
    • Wrap-up panel.

    Session objectives:

    • Learn the importance of innovation in developing hepatitis B and C control programs, policies and products.
    • Understand new products for hepatitis B and C control that could accelerate detection, treatment and retention.
    • Discuss new policies for expanding access to hepatitis B and C testing, treatment and prevention strategies.
    • Learn about new programs and public health interventions to optimize comprehensive hepatitis care.
  • 15:30

    Summary and handover to WHS19 host country

    Time: 15:30

    A summary of the learning from the World Hepatitis Summit 2017 and a handover to the hosts for 2019.

    Presentations:

    • Event summary and closing thoughts from the Chair.
    • Handover to the World Hepatitis Summit 2019 nation host.
  • 16:15

    Close of the World Hepatitis Summit 2017

    Time: 16:15

Please note this agenda is a draft and subject to change.
Updated
Programme Now Live!
Updated
Programme
Now Live!